gamma-aminobutyric acid has been researched along with Multiple Sclerosis in 71 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis." | 9.14 | Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010) |
| "To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 9.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 9.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "To examine the efficacy of gabapentin in the treatment of spasticity and painful muscle spasms in patients with multiple sclerosis." | 9.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 9.06 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine." | 7.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| "With gabapentin, 10 of 13 patients with nystagmus secondary to multiple sclerosis (MS) showed some improvement." | 7.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| "The authors present the case of a 49-year-old woman with disabling bilateral upper-extremity cerebellar tremor that resolved unexpectedly after placement of an intrathecal baclofen pump for lower-extremity spasticity." | 7.72 | Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. ( Lenz, FA; North, RB; Ohara, S; Weiss, N, 2003) |
| "This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy." | 7.70 | Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998) |
| "We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)." | 7.70 | An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998) |
| "Isonicotinic acid hydrazide (isoniazid) was evaluated in five patients as a treatment for the control of severe cerebellar action tremor occurring in multiple sclerosis." | 7.67 | The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. ( Francis, DA; Grundy, D; Heron, JR, 1986) |
| "Four patients with disabling action tremor in the setting of MS were treated with isoniazid (800 to 1200 mg per day)." | 7.66 | Treatment of action tremor in multiple sclerosis with isoniazid. ( Hallett, M; Mullally, W; Sabra, AF; Sudarsky, L, 1982) |
| "Gabapentin reduces the impairment of spasticity, compared with placebo, without the side effects of worsening concentration and fatigue." | 6.69 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Progabide was associated with lessened spasticity." | 6.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Progabide is an effective antispastic agent and its antispastic effect is not accompanied by increased motor weakness." | 6.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 6.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Patients with congenital nystagmus showed reduction of nystagmus and their VA changes depended on the ocular pathology." | 5.33 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| "Four patients with disabling action tremor in the setting of MS were treated with isoniazid (800 to 1200 mg per day)." | 5.26 | Treatment of action tremor in multiple sclerosis with isoniazid. ( Hallett, M; Mullally, W; Sabra, AF; Sudarsky, L, 1982) |
| "A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis." | 5.14 | Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010) |
| "To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 5.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 5.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "To examine the efficacy of gabapentin in the treatment of spasticity and painful muscle spasms in patients with multiple sclerosis." | 5.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 5.06 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| " However, two randomised placebo-controlled studies have recently emerged demonstrating efficacy of pregabalin in reducing central neuropathic pain due to spinal cord injury and central poststroke pain." | 4.84 | Pregabalin in the management of central neuropathic pain. ( Gray, P, 2007) |
| "Transcriptomic and proteomic analyses of multiple sclerosis (MS) lesions indicate alterations in the gamma-aminobutyric acid (GABA) inhibitory system, suggesting its involvement in the disease process." | 3.79 | Systemic treatment with the inhibitory neurotransmitter γ-aminobutyric acid aggravates experimental autoimmune encephalomyelitis by affecting proinflammatory immune responses. ( Carmans, S; Hellings, N; Hendriks, JJ; Rigo, JM; Slaets, H; Stinissen, P; Thewissen, K, 2013) |
| "The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine." | 3.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| "With gabapentin, 10 of 13 patients with nystagmus secondary to multiple sclerosis (MS) showed some improvement." | 3.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| "The authors present the case of a 49-year-old woman with disabling bilateral upper-extremity cerebellar tremor that resolved unexpectedly after placement of an intrathecal baclofen pump for lower-extremity spasticity." | 3.72 | Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. ( Lenz, FA; North, RB; Ohara, S; Weiss, N, 2003) |
| "A 40-year-old patient with acquired horizontal and vertical nystagmus and severe oscillopsia secondary to multiple sclerosis had combined treatment with gabapentin and a vertical Kestenbaum-type procedure." | 3.71 | Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. ( Constantinescu, CS; Gottlob, I; Jain, S; Proudlock, F, 2002) |
| "We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)." | 3.70 | An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998) |
| "This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy." | 3.70 | Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998) |
| "Isonicotinic acid hydrazide (isoniazid) was evaluated in five patients as a treatment for the control of severe cerebellar action tremor occurring in multiple sclerosis." | 3.67 | The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. ( Francis, DA; Grundy, D; Heron, JR, 1986) |
| "Four patients with disabling action tremor in the setting of MS were treated with isoniazid (800 to 1200 mg per day)." | 3.66 | Treatment of action tremor in multiple sclerosis with isoniazid. ( Hallett, M; Mullally, W; Sabra, AF; Sudarsky, L, 1982) |
| "Gabapentin reduces the impairment of spasticity, compared with placebo, without the side effects of worsening concentration and fatigue." | 2.69 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Progabide is an effective antispastic agent and its antispastic effect is not accompanied by increased motor weakness." | 2.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 2.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Progabide was associated with lessened spasticity." | 2.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "The available studies on spasticity treatment offer some insight to guide clinical practice but are of variable methodological quality." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| "Central neuropathic pain is a painful condition, often severe, that occurs in a person who is already affected by an injury or disease of the brain or spinal cord." | 2.44 | Pregabalin in the management of central neuropathic pain. ( Gray, P, 2007) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Fatigue is a common symptom in patients with multiple sclerosis (MS) with unknown pathophysiology." | 1.62 | Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue. ( Al-Iedani, O; Arm, J; Lea, R; Lechner-Scott, J; Oeltzschner, G; Ramadan, S, 2021) |
| "Physical fatigue was negatively correlated with GABA+ in SMC and PFC (r = -0." | 1.62 | Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue. ( Al-Iedani, O; Arm, J; Lea, R; Lechner-Scott, J; Oeltzschner, G; Ramadan, S, 2021) |
| "Mechanical allodynia was fully developed by 28-30days post-immunization (p." | 1.40 | Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014) |
| "Although mouse models of experimental autoimmune encephalomyelitis (EAE) have provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe motor impairments confound quantitative assessment of pain behaviors over the disease course." | 1.40 | Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014) |
| "Median subjective spasticity scores increased from 4 at baseline to 6 at lowest dose (p < 0." | 1.39 | Spasticity increases during pregabalin withdrawal. ( Baguley, IJ; Braid, JJ; Kirker, SG, 2013) |
| "Mean pre-withdrawal pregabalin dosage was 386 mg/day, decreasing to 70 mg/day at mean lowest dosage." | 1.39 | Spasticity increases during pregabalin withdrawal. ( Baguley, IJ; Braid, JJ; Kirker, SG, 2013) |
| "Acquired pendular nystagmus (APN) occurs with multiple sclerosis (MS) and oculopalatal tremor (OPT); distinct features of the nystagmus have led to the development of separate models for their pathogenesis." | 1.37 | Pharmacological tests of hypotheses for acquired pendular nystagmus. ( Leigh, RJ; Optican, LM; Shaikh, AG; Thurtell, MJ, 2011) |
| "Patients with congenital nystagmus showed reduction of nystagmus and their VA changes depended on the ocular pathology." | 1.33 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| " The aim of the study was to evaluate the frequency of AED utilisation and reported adverse events, in a cohort of MS patients." | 1.33 | Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005) |
| "Lamotrigine (LMT) was prescribed in 22 patients, with adverse effects reported in 4 cases, none mimicking a relapse." | 1.33 | Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005) |
| "Gabapentin (GBP) was prescribed in 94 patients, with adverse effects reported in 16 cases and in one case mimicked a relapse." | 1.33 | Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005) |
| "Carbamazepine (CBZ) was prescribed in 36 patients, with adverse effects reported in 20 cases, of which 12 mimicked a relapse." | 1.33 | Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005) |
| "Acquired Pendular Nystagmus (APN) may cause distressing visual symptoms in patients who are already suffering a severe general disease." | 1.31 | Improvement of acquired pendular nystagmus by gabapentin: case report. ( Fabre, K; Smet-Dieleman, H; Zeyen, T, 2001) |
| "Currently there is no effective medical treatment for the dysarthria of MS which occurs as a result of lesions to the cerebellum and its outflow tracts." | 1.29 | Resolution of dysarthria in multiple sclerosis by treatment with weak electromagnetic fields. ( Sandyk, R, 1995) |
| "In patients with Huntington's disease, on administration of isoniazid at 900 mg/day, along with pyridoxine at 100 mg/day, a 4-fold increase of both free (P less than 0." | 1.27 | Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. ( Manyam, BV; Tremblay, RD, 1984) |
| "gamma-Aminobutyric acid (GABA) was measured in CSF as such and following acid hydrolysis by the ion-exchange/fluorometric method." | 1.27 | Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. ( Manyam, BV; Tremblay, RD, 1984) |
| "Four patients with disabling action tremor in the setting of MS were treated with isoniazid (800 to 1200 mg per day)." | 1.26 | Treatment of action tremor in multiple sclerosis with isoniazid. ( Hallett, M; Mullally, W; Sabra, AF; Sudarsky, L, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (18.31) | 18.7374 |
| 1990's | 10 (14.08) | 18.2507 |
| 2000's | 19 (26.76) | 29.6817 |
| 2010's | 23 (32.39) | 24.3611 |
| 2020's | 6 (8.45) | 2.80 |
| Authors | Studies |
|---|---|
| Stamoula, Е | 1 |
| Ainatzoglou, A | 1 |
| Dardalas, I | 1 |
| Vavilis, T | 1 |
| Stamatellos, VP | 1 |
| Siafis, S | 1 |
| Psathas, T | 1 |
| Boskou, I | 1 |
| Papazisis, G | 1 |
| Marchese, E | 1 |
| Valentini, M | 1 |
| Di Sante, G | 1 |
| Cesari, E | 1 |
| Adinolfi, A | 1 |
| Corvino, V | 1 |
| Ria, F | 1 |
| Sette, C | 1 |
| Geloso, MC | 1 |
| Arm, J | 1 |
| Oeltzschner, G | 1 |
| Al-Iedani, O | 1 |
| Lea, R | 1 |
| Lechner-Scott, J | 1 |
| Ramadan, S | 1 |
| Tian, J | 1 |
| Song, M | 1 |
| Kaufman, DL | 1 |
| Kantorová, E | 2 |
| Hnilicová, P | 2 |
| Bogner, W | 2 |
| Grendár, M | 2 |
| Čierny, D | 2 |
| Hečková, E | 2 |
| Strasser, B | 2 |
| Ružinák, R | 1 |
| Zeleňák, K | 2 |
| Kurča, E | 2 |
| Grossmann, J | 1 |
| Kováčová, S | 1 |
| Modica, CM | 1 |
| Schweser, F | 1 |
| Sudyn, ML | 1 |
| Bertolino, N | 1 |
| Preda, M | 1 |
| Polak, P | 1 |
| Siebert, DM | 1 |
| Krawiecki, JC | 1 |
| Sveinsson, M | 1 |
| Hagemeier, J | 1 |
| Dwyer, MG | 1 |
| Pol, S | 1 |
| Zivadinov, R | 1 |
| Kiljan, S | 1 |
| Prins, M | 1 |
| Baselmans, BM | 1 |
| Bol, JGJM | 1 |
| Schenk, GJ | 1 |
| van Dam, AM | 1 |
| Bhattacharyya, PK | 1 |
| Phillips, MD | 1 |
| Stone, LA | 1 |
| Bermel, RA | 1 |
| Lowe, MJ | 1 |
| Paul, AM | 1 |
| Branton, WG | 1 |
| Walsh, JG | 1 |
| Polyak, MJ | 1 |
| Lu, JQ | 1 |
| Baker, GB | 1 |
| Power, C | 1 |
| Khan, N | 1 |
| Woodruff, TM | 1 |
| Smith, MT | 1 |
| Mandolesi, G | 1 |
| Gentile, A | 1 |
| Musella, A | 1 |
| Centonze, D | 2 |
| Steinman, L | 2 |
| De Stefano, N | 2 |
| Giorgio, A | 1 |
| Cawley, N | 1 |
| Solanky, BS | 1 |
| Muhlert, N | 1 |
| Tur, C | 1 |
| Edden, RA | 1 |
| Wheeler-Kingshott, CA | 1 |
| Miller, DH | 2 |
| Thompson, AJ | 2 |
| Ciccarelli, O | 2 |
| Kanceva, R | 1 |
| Stárka, L | 1 |
| Kancheva, L | 1 |
| Hill, M | 1 |
| Veliková, M | 1 |
| Havrdová, E | 1 |
| Trojano, M | 1 |
| Otero-Romero, S | 1 |
| Sastre-Garriga, J | 1 |
| Comi, G | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Vermersch, P | 1 |
| Gold, R | 1 |
| Montalban, X | 2 |
| Prinsen, H | 1 |
| de Graaf, RA | 1 |
| Mason, GF | 1 |
| Pelletier, D | 1 |
| Juchem, C | 1 |
| Nantes, JC | 1 |
| Proulx, S | 1 |
| Zhong, J | 1 |
| Holmes, SA | 1 |
| Narayanan, S | 1 |
| Brown, RA | 1 |
| Hoge, RD | 1 |
| Koski, L | 1 |
| Heetla, HW | 1 |
| Staal, MJ | 1 |
| Kliphuis, C | 1 |
| van Laar, T | 1 |
| Starck, M | 1 |
| Albrecht, H | 1 |
| Pöllmann, W | 1 |
| Dieterich, M | 1 |
| Straube, A | 1 |
| Bhat, R | 1 |
| Axtell, R | 1 |
| Mitra, A | 1 |
| Miranda, M | 1 |
| Lock, C | 1 |
| Tsien, RW | 1 |
| Bittner, S | 1 |
| Höhn, K | 1 |
| Göbel, K | 1 |
| Kleinschnitz, C | 1 |
| Wiendl, H | 1 |
| Meuth, SG | 1 |
| Shaikh, AG | 1 |
| Thurtell, MJ | 1 |
| Optican, LM | 1 |
| Leigh, RJ | 2 |
| Jin, Z | 1 |
| Mendu, SK | 1 |
| Birnir, B | 1 |
| Rossi, S | 1 |
| Studer, V | 1 |
| Motta, C | 1 |
| De Chiara, V | 1 |
| Barbieri, F | 1 |
| Bernardi, G | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Carmans, S | 1 |
| Hendriks, JJ | 1 |
| Slaets, H | 1 |
| Thewissen, K | 1 |
| Stinissen, P | 1 |
| Rigo, JM | 1 |
| Hellings, N | 1 |
| Braid, JJ | 1 |
| Kirker, SG | 1 |
| Baguley, IJ | 1 |
| Jain, S | 1 |
| Proudlock, F | 1 |
| Constantinescu, CS | 1 |
| Gottlob, I | 3 |
| Fabre, K | 1 |
| Smet-Dieleman, H | 1 |
| Zeyen, T | 1 |
| Demakova, EV | 1 |
| Korobov, VP | 1 |
| Lemkina, LM | 1 |
| Weiss, N | 1 |
| North, RB | 1 |
| Ohara, S | 1 |
| Lenz, FA | 1 |
| Yetimalar, Y | 1 |
| Gürgör, N | 1 |
| Başoğlu, M | 1 |
| Hsu, C | 1 |
| Sliwa, JA | 1 |
| Sarrigiannis, P | 1 |
| Tsakanicas, C | 1 |
| Anagnostouli, M | 1 |
| Karandreas, N | 1 |
| Solaro, C | 5 |
| Brichetto, G | 1 |
| Battaglia, MA | 1 |
| Messmer Uccelli, M | 2 |
| Mancardi, GL | 5 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Shery, T | 1 |
| Proudlock, FA | 1 |
| Sarvananthan, N | 2 |
| McLean, RJ | 1 |
| Choudhuri, I | 1 |
| Gray, P | 1 |
| Manson, SC | 1 |
| Wegner, C | 1 |
| Filippi, M | 1 |
| Barkhof, F | 1 |
| Beckmann, C | 1 |
| Enzinger, C | 1 |
| Fazekas, F | 1 |
| Agosta, F | 1 |
| Gass, A | 1 |
| Hirsch, J | 1 |
| Johansen-Berg, H | 1 |
| Kappos, L | 1 |
| Korteweg, T | 1 |
| Polman, C | 1 |
| Mancini, L | 1 |
| Manfredonia, F | 1 |
| Marino, S | 1 |
| Palace, J | 1 |
| Rocca, M | 1 |
| Ropele, S | 1 |
| Rovira, A | 1 |
| Smith, S | 1 |
| Thompson, A | 1 |
| Thornton, J | 1 |
| Yousry, T | 1 |
| Frank, JA | 1 |
| Matthews, PM | 1 |
| Christensen, SE | 1 |
| Dupont, E | 1 |
| Mondrup, K | 1 |
| Olivarius, BF | 1 |
| Orskov, H | 1 |
| Manyam, BV | 1 |
| Tremblay, RD | 1 |
| Perry, TL | 1 |
| Ito, M | 1 |
| Jones, K | 1 |
| Hansen, S | 1 |
| Manyam, NV | 1 |
| Katz, L | 1 |
| Hare, TA | 1 |
| Gerber, JC | 1 |
| Grossman, MH | 1 |
| Sabra, AF | 1 |
| Hallett, M | 1 |
| Sudarsky, L | 1 |
| Mullally, W | 1 |
| Sandyk, R | 1 |
| Mueller, ME | 1 |
| Gruenthal, M | 1 |
| Olson, WL | 1 |
| Olson, WH | 1 |
| Samkoff, LM | 1 |
| Daras, M | 1 |
| Tuchman, AJ | 1 |
| Koppel, BS | 1 |
| Houtchens, MK | 1 |
| Richert, JR | 1 |
| Sami, A | 1 |
| Rose, JW | 1 |
| Gade-Andavolu, R | 1 |
| MacMurray, JP | 1 |
| Blake, H | 1 |
| Muhleman, D | 1 |
| Tourtellotte, W | 1 |
| Comings, DE | 1 |
| Lunardi, GL | 1 |
| Capello, E | 1 |
| Inglese, M | 1 |
| Uccelli, A | 2 |
| Khan, OA | 1 |
| Uccelli, MM | 2 |
| Tan, J | 1 |
| Town, T | 1 |
| Paris, D | 1 |
| Placzek, A | 1 |
| Parker, T | 1 |
| Crawford, F | 1 |
| Yu, H | 1 |
| Humphrey, J | 1 |
| Mullan, M | 1 |
| Cutter, NC | 1 |
| Scott, DD | 1 |
| Johnson, JC | 1 |
| Whiteneck, G | 1 |
| Guglieri, P | 1 |
| Inobe, J | 1 |
| Arakawa, T | 1 |
| Mori, T | 1 |
| Kumamoto, T | 1 |
| Tsuda, T | 1 |
| Bandini, F | 1 |
| Castello, E | 1 |
| Mazzella, L | 1 |
| Stahl, JS | 1 |
| Rottach, KG | 1 |
| Averbuch-Heller, L | 1 |
| von Maydell, RD | 1 |
| Collins, SD | 1 |
| Schapiro, RT | 1 |
| Achar, VS | 1 |
| Welch, KM | 1 |
| Chabi, E | 1 |
| Bartosh, K | 1 |
| Meyer, JS | 1 |
| Levine, IM | 1 |
| Jossmann, PB | 1 |
| DeAngelis, V | 1 |
| Rudick, RA | 1 |
| Breton, D | 1 |
| Krall, RL | 1 |
| Francis, DA | 1 |
| Grundy, D | 1 |
| Heron, JR | 1 |
| Basmajian, JV | 1 |
| Yucel, V | 1 |
| Knutsson, E | 1 |
| Lindblom, U | 1 |
| Mårtensson, A | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Pedersen, E | 1 |
| Arlien-Soborg, P | 1 |
| Mai, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects[NCT05808101] | 120 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury[NCT00223873] | 30 participants | Interventional | 2002-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for gamma-aminobutyric acid and Multiple Sclerosis
| Article | Year |
|---|---|
Effects of GABAergic Agents on Multiple Sclerosis. A Narrative Review of
Topics: Animals; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; GABA Agonists; gamma-A | 2023 |
IL-1β dependent cerebellar synaptopathy in a mouse mode of multiple sclerosis.
Topics: Animals; Cerebellum; Encephalomyelitis, Autoimmune, Experimental; gamma-Aminobutyric Acid; Glutamic | 2015 |
No quiet surrender: molecular guardians in multiple sclerosis brain.
Topics: alpha-Crystallin B Chain; Amyloid; Anti-Inflammatory Agents; Antioxidants; Brain; Cytokines; Female; | 2015 |
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor | 2011 |
GABA is an effective immunomodulatory molecule.
Topics: Animals; Arthritis, Rheumatoid; Diabetes Mellitus, Type 1; gamma-Aminobutyric Acid; Humans; Mice; Mu | 2013 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
Pregabalin in the management of central neuropathic pain.
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Humans; Multiple Sclerosis; Neuralgia; Pregabalin; Ris | 2007 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adolescent; Adult; Aminobutyrates; Animals; Chlorobenzenes; Chronic Disease; Clinical Trials as Topi | 1974 |
11 trials available for gamma-aminobutyric acid and Multiple Sclerosis
| Article | Year |
|---|---|
Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin.
Topics: Adult; Amines; Brain Stem; Clinical Protocols; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose | 2010 |
Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2004 |
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid | 1997 |
Open label gabapentin treatment for pain in multiple sclerosis.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab | 1997 |
Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cross-Over Studies; C | 2000 |
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.
Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2000 |
Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Electrooculography; Female; Gabapentin; gamma- | 2001 |
Liorseal, a new muscle relaxant in the treatment of spasticity--a double-blind quantitative evaluation.
Topics: Adult; Aminobutyrates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Meth | 1977 |
The GABA-agonist progabide for spasticity in multiple sclerosis.
Topics: Adult; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Multiple Scleros | 1987 |
Effects of a GABA--derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study.
Topics: Administration, Oral; Adult; Aminobutyrates; Clinical Trials as Topic; Electromyography; Female; gam | 1974 |
Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adolescent; Adult; Aminobutyrates; Animals; Chlorobenzenes; Chronic Disease; Clinical Trials as Topi | 1974 |
51 other studies available for gamma-aminobutyric acid and Multiple Sclerosis
| Article | Year |
|---|---|
Alternative splicing of neurexins 1-3 is modulated by neuroinflammation in the prefrontal cortex of a murine model of multiple sclerosis.
Topics: Alternative Splicing; Animals; Calcium-Binding Proteins; Cognitive Dysfunction; Encephalitis; Enceph | 2021 |
Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue.
Topics: Brain; Fatigue; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Imagin | 2021 |
Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis.
Topics: Animals; Antigen Presentation; Antigen-Presenting Cells; Cell Proliferation; Central Nervous System; | 2021 |
Positivity of oligoclonal bands in the cerebrospinal fluid predisposed to metabolic changes and rearrangement of inhibitory/excitatory neurotransmitters in subcortical brain structures in multiple sclerosis.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Multiple Sclerosis; Neurotransmitter Agents; Oligoclonal Ban | 2021 |
Neurocognitive performance in relapsing-remitting multiple sclerosis patients is associated with metabolic abnormalities of the thalamus but not the hippocampus- GABA-edited 1H MRS study.
Topics: gamma-Aminobutyric Acid; Hippocampus; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multip | 2022 |
Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.
Topics: Animals; Basal Ganglia; Cell Line; Corpus Callosum; Crotonates; Disease Models, Animal; Drug Evaluat | 2017 |
Enhanced GABAergic Immunoreactivity in Hippocampal Neurons and Astroglia of Multiple Sclerosis Patients.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Demyelinating Diseases; Female; gamma-Aminobutyric Acid; | 2019 |
Sensorimotor cortex gamma-aminobutyric acid concentration correlates with impaired performance in patients with MS.
Topics: Adult; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscopy; Male; M | 2013 |
GABA transport and neuroinflammation are coupled in multiple sclerosis: regulation of the GABA transporter-2 by ganaxolone.
Topics: Animals; Astrocytes; Cells, Cultured; Encephalomyelitis, Autoimmune, Experimental; Female; Frontal L | 2014 |
Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Topics: Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclohexanecarboxyli | 2014 |
GABA: a new imaging biomarker of neurodegeneration in multiple sclerosis?
Topics: Brain; Disabled Persons; Female; gamma-Aminobutyric Acid; Humans; Male; Multiple Sclerosis | 2015 |
Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis.
Topics: Adult; Aspartic Acid; Brain; Disability Evaluation; Disabled Persons; Female; gamma-Aminobutyric Aci | 2015 |
Increased serum levels of C21 steroids in female patients with multiple sclerosis.
Topics: Adult; Biomarkers; Female; gamma-Aminobutyric Acid; Gas Chromatography-Mass Spectrometry; Humans; Mi | 2015 |
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli | 2016 |
Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T.
Topics: Adult; Biomarkers; Brain; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutathione; Humans; Magne | 2017 |
GABA and glutamate levels correlate with MTR and clinical disability: Insights from multiple sclerosis.
Topics: Adult; Disabled Persons; Female; gamma-Aminobutyric Acid; Glutamic Acid; Gray Matter; Humans; Male; | 2017 |
The incidence and management of tolerance in intrathecal baclofen therapy.
Topics: Adolescent; Adult; Aged; Baclofen; Cohort Studies; Dose-Response Relationship, Drug; Drug Tolerance; | 2009 |
Inhibitory role for GABA in autoimmune inflammation.
Topics: 4-Aminobutyrate Transaminase; Animals; Antigen-Presenting Cells; Blotting, Western; Cells, Cultured; | 2010 |
Pharmacological tests of hypotheses for acquired pendular nystagmus.
Topics: Amines; Baclofen; Cerebellar Cortex; Cyclohexanecarboxylic Acids; Eye Movements; Gabapentin; gamma-A | 2011 |
Inflammation inhibits GABA transmission in multiple sclerosis.
Topics: Adult; Animals; Anti-Inflammatory Agents; Brain; Case-Control Studies; Cytokines; Female; gamma-Amin | 2012 |
Systemic treatment with the inhibitory neurotransmitter γ-aminobutyric acid aggravates experimental autoimmune encephalomyelitis by affecting proinflammatory immune responses.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; GABA Agents; gamma-Aminobutyric Acid; | 2013 |
Spasticity increases during pregabalin withdrawal.
Topics: Analgesics; Anticonvulsants; Brain Injuries; Cerebral Palsy; Drug Administration Schedule; Female; g | 2013 |
Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis.
Topics: Acetates; Adult; Amines; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Diplopia; Excitator | 2002 |
Improvement of acquired pendular nystagmus by gabapentin: case report.
Topics: Acetates; Administration, Oral; Amines; Baclofen; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2001 |
[Determination of gamma-aminobutyric acid concentration and activity of glutamate decarboxylase in blood serum of patients with multiple sclerosis].
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Male; Middle Ag | 2003 |
Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report.
Topics: Baclofen; Cerebellum; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; Infusion Pumps, Implan | 2003 |
Phantom breast pain as a source of functional loss.
Topics: Acetates; Activities of Daily Living; Amines; Anti-Anxiety Agents; Breast Neoplasms; Carcinoma in Si | 2004 |
Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study.
Topics: Adult; Amines; Baclofen; Blinking; Brain; Clonazepam; Cyclohexanecarboxylic Acids; Electromyography; | 2004 |
Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study.
Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Follow-Up Studies; | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gab | 2006 |
Survey of management of acquired nystagmus in the United Kingdom.
Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists; | 2007 |
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition.
Topics: Adult; Cerebral Cortex; Corpus Callosum; Female; gamma-Aminobutyric Acid; Hand; Humans; Magnetic Res | 2008 |
Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluid.
Topics: Adult; Aged; Alzheimer Disease; Atrophy; Brain Diseases; Female; gamma-Aminobutyric Acid; Humans; Hu | 1984 |
Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid.
Topics: Adult; Age Factors; Aged; Cerebellar Ataxia; Dementia; Epilepsy; gamma-Aminobutyric Acid; Humans; Hu | 1984 |
Elevation of gamma-aminobutyric acid in human brain may increase dopaminergic neuronal function.
Topics: Brain; Brain Chemistry; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Huntington Dis | 1984 |
Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders.
Topics: Brain Chemistry; Cerebellar Diseases; Creatine Kinase; Dementia; Diet; Encephalitis; Epilepsy; gamma | 1980 |
Treatment of action tremor in multiple sclerosis with isoniazid.
Topics: Adult; Animals; Brain Chemistry; Electromyography; Female; gamma-Aminobutyric Acid; Humans; Isoniazi | 1982 |
Resolution of dysarthria in multiple sclerosis by treatment with weak electromagnetic fields.
Topics: Brain; Dysarthria; Electromagnetic Fields; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonan | 1995 |
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1997 |
Association between the gamma-aminobutyric acid A3 receptor gene and multiple sclerosis.
Topics: Alleles; Chi-Square Distribution; Cytokines; Female; gamma-Aminobutyric Acid; Genetic Linkage; Gluta | 1998 |
An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 1998 |
Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1998 |
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset.
Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis | 1999 |
Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis.
Topics: Animals; CD4-Positive T-Lymphocytes; CD40 Antigens; CD40 Ligand; Cell Communication; Cells, Cultured | 1999 |
[Acquired pendular nystagmus associated with the lesion of tegmentum mesencephali in a patient with probable multiple sclerosis].
Topics: Adult; Brain Diseases; Clonazepam; Diazepam; Female; gamma-Aminobutyric Acid; Humans; Multiple Scler | 2000 |
A pilot study of gabapentin as treatment for acquired nystagmus.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Stem; Cerebrovascular Disorders; Cyclohexanecarboxyl | 1996 |
Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease.
Topics: Aminobutyrates; Cerebrovascular Disorders; Dementia; Epilepsy, Post-Traumatic; Epilepsy, Temporal Lo | 1976 |
The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry.
Topics: Adult; Brain; Female; gamma-Aminobutyric Acid; Humans; Isoniazid; Light; Male; Middle Aged; Multiple | 1986 |
Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis.
Topics: Adolescent; Adult; Aged; Aminobutyrates; Cold Temperature; Female; gamma-Aminobutyric Acid; Humans; | 1974 |
The mode of action of the gaba derivative baclofen in human spasticy.
Topics: Achilles Tendon; Aminobutyrates; Depression, Chemical; gamma-Aminobutyric Acid; Humans; Multiple Scl | 1974 |